Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
We would like to thank Nocturne et al 1 for their comments regarding our paper,2 giving us the opportunity to clarify possible obscurities and signify the predictive value of low miR200b-5p levels in minor salivary glands (MSGs) for the development of lymphoma in primary Sjögren’s syndrome (pSS).
Our findings disclosed that low miR200b-5p levels in MSGs of patients with pSS (1) strongly discriminate patients with SS who will develop or have lymphoma from those who will not, (2) independently predict lymphoma development, (3) are reduced long before the clinical onset of lymphoma, enabling thus, the identification and efficient monitoring of high-risk patients and (4) may have an application in the monitoring of therapeutic response. These findings strongly support the predictive value of miR200b-5p for monitoring lymphoma development in pSS. Furthermore, the simplicity of the detection assay facilitates the easy and reproducible application worldwide.
As addressed in the original manuscript, this new biomarker was found to correlate with several histological, clinical and laboratory parameters previously associated with lymphoma development, including biopsy focus score and infiltration by various types by infiltrating cells.2 Although the later associations …
Handling editor Josef S Smolen
Contributors EKK analysed the data and wrote the paper along with AGT. AP and MV evaluated the clinical data of NHL patients, whereas ADP performed statistical analyses. AGT and EKK had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Funding The research has been financed by a research grant from the Greek Rheumatology Society and Professional Association of Rheumatologists and the European-funded multicentric protocol ‘HARMONIzation and integrative analysis of regional, national and international Cohorts on primary Sjögren’s Syndrome (pSS) towards improved stratification, treatment and health policy making’ (HarmonicSS; H2020-SC1-2016; Grant Agreement No. 731944).
Competing interests None declared.
Patient consent Not required.
Ethics approval Ethics Committee of School of Medicine, National and Kapodistrian University of Athens, Greece (Protocol No. 1516023881).
Provenance and peer review Commissioned; internally peer reviewed.